beta-lapachone (HK-660S) / Curome Biosci - LARVOL DELTA

Correspondence to editorials (CMH-2025-0699) on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial". (PubMed, Clin Mol Hepatol) - No abstract available

Journal • P2a data

Letter to the editor on" Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. ". (PubMed, Clin Mol Hepatol) - No abstract available

Journal • P2a data

Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis (clinicaltrials.gov) - P2 | N=105 | Not yet recruiting | Sponsor: CuromeBiosciences

New P2 trial

Critical Considerations in Evaluating the Therapeutic Potential of HK-660S for Primary Sclerosing Cholangitis. (PubMed, Clin Mol Hepatol) - No abstract available

Journal • Hepatology

Correspondence to editorials on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial". (PubMed, Clin Mol Hepatol) - No abstract available

Journal • P2a data • Hepatology

Challenges and Innovations in PSC Clinical Trials: Evaluating HK-660S and the Path Forward. (PubMed, Clin Mol Hepatol) - No abstract available

Journal

SAFETY AND EFFICACY OF HK-660S VERSUS PLACEBO IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A TRIAL (AASLD 2024) - "This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in PSC... This 12-week proof-of-concept trial demonstrated that HK-660S is well-tolerated among PSC patients and may improve bile duct strictures and decrease serum ALP levels. Further randomised trials with long-term follow-up are necessary to confirm these promising results."

Clinical • P2a data • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Oncology • Primary Biliary Cholangitis

Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. (PubMed, Clin Mol Hepatol) - "This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in PSC...HK-660S is well-tolerated among patients with PSC and may improve bile duct strictures, decrease serum ALP levels, and reduce liver fibrosis. (cris.nih.go.kr, Number KCT0006590)."

Clinical • Journal • P2a data • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

A randomized phase II proof-of-concept study of beta-lapachone in patients with primary sclerosing cholangitis (EASL-ILC 2024) - P2 | "This 12-week proof-of-concept clinical trial demonstrated that HK-660S was well- tolerated in PSC patients and had the potential to decrease serum ALP levels. Further phase 3 randomized trials with long-term follow-up are warranted to validate these promising results. (ClinicalTrials.gov NCT05866809)"

Clinical • P2 data • Cholestasis • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Oncology • Primary Biliary Cholangitis

Beta-lapachone ameliorates the progression of primary sclerosing cholangitis pathogenesis in rodent models. (PubMed, Life Sci) - "This study provided a new concept for PSC treatment, suggesting that pharmacological stimulation of the NAD synthetic pathway and Abcb4 via βL ameliorates PSC pathogenesis."

Journal • Preclinical • Cholestasis • Fibrosis • Hepatology • Immunology • Inflammation • ABCB4 • SIRT1

Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis (clinicaltrials.gov) - P2 | N=23 | Completed | Sponsor: CuromeBiosciences | Active, not recruiting ➔ Completed

Trial completion • Hepatology

Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis (clinicaltrials.gov) - P2 | N=23 | Active, not recruiting | Sponsor: CuromeBiosciences

New P2 trial • Hepatology